Literature DB >> 31187164

[Pharmacotherapy of chronic neuropathic pain].

J Otto1, J Forstenpointner1, A Binder2, R Baron3.   

Abstract

Chronic neuropathic pain has a prevalence of 6.9-10% in the general population. The current recommendations for treatment are presented based on a literature search. Neuropathic pain requires the use of co-analgesic, antidepressant, anticonvulsant drugs and topical agents because non-opioid analgesic drugs are usually ineffective. The use of meta-analyses tricyclic antidepressants, selective serotonin-norephinephrine reuptake inhibitors, and calcium channel anticonvulsants are recommended as the drugs of first choice. Under certain conditions chronic neuropathic pain can be treated with opioids. Topical therapeutics are only used to treat peripheral neuropathic pain. At present the use of drugs is independent of the etiology of the pain. Comorbidities, concomitant medication, potential side effects and patients' age have to be considered in treatment planning.

Entities:  

Keywords:  Analgesics, opioids; Antidepressive agents, tricyclic; Calcium channels; Neuralgia; Serotonin and noradrenaline reuptake inhibitors

Mesh:

Substances:

Year:  2019        PMID: 31187164     DOI: 10.1007/s00108-019-0627-2

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  12 in total

1.  [Integrative assessment of evidence in healthcare: the GRADE system].

Authors:  Holger Schünemann
Journal:  Z Evid Fortbild Qual Gesundhwes       Date:  2009

2.  A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy.

Authors:  Aaron I Vinik; Douglas Y Shapiro; Christine Rauschkolb; Bernd Lange; Keith Karcher; Deborah Pennett; Mila S Etropolski
Journal:  Diabetes Care       Date:  2014-05-21       Impact factor: 19.112

3.  Improving adherence with medication: a selective literature review based on the example of hypertension treatment.

Authors:  Jan Matthes; Christian Albus
Journal:  Dtsch Arztebl Int       Date:  2014-01-24       Impact factor: 5.594

4.  Long-term opioid use in non-cancer pain.

Authors:  Winfried Häuser; Fritjof Bock; Peter Engeser; Thomas Tölle; Anne Willweber-Strumpfe; Frank Petzke
Journal:  Dtsch Arztebl Int       Date:  2014-10-24       Impact factor: 5.594

Review 5.  Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment.

Authors:  Ralf Baron; Andreas Binder; Gunnar Wasner
Journal:  Lancet Neurol       Date:  2010-08       Impact factor: 44.182

6.  A randomized, controlled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers.

Authors:  William R Kennedy; Geertrui F Vanhove; Shiao-Ping Lu; Jeffrey Tobias; Keith R Bley; David Walk; Gwen Wendelschafer-Crabb; Donald A Simone; Mona M Selim
Journal:  J Pain       Date:  2010-04-18       Impact factor: 5.820

7.  Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study.

Authors:  Ralf Baron; Rudolf Likar; Emilio Martin-Mola; Francisco J Blanco; Lieven Kennes; Matthias Müller; Dietmar Falke; Ilona Steigerwald
Journal:  Pain Pract       Date:  2015-06-12       Impact factor: 3.183

8.  Potentially inappropriate medications in the elderly: the PRISCUS list.

Authors:  Stefanie Holt; Sven Schmiedl; Petra A Thürmann
Journal:  Dtsch Arztebl Int       Date:  2010-08-09       Impact factor: 5.594

Review 9.  Neuropathic pain in the general population: a systematic review of epidemiological studies.

Authors:  O van Hecke; Sophie K Austin; Rafi A Khan; B H Smith; N Torrance
Journal:  Pain       Date:  2013-11-26       Impact factor: 6.961

Review 10.  Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis.

Authors:  Nanna B Finnerup; Nadine Attal; Simon Haroutounian; Ewan McNicol; Ralf Baron; Robert H Dworkin; Ian Gilron; Maija Haanpää; Per Hansson; Troels S Jensen; Peter R Kamerman; Karen Lund; Andrew Moore; Srinivasa N Raja; Andrew S C Rice; Michael Rowbotham; Emily Sena; Philip Siddall; Blair H Smith; Mark Wallace
Journal:  Lancet Neurol       Date:  2015-01-07       Impact factor: 44.182

View more
  3 in total

1.  Targeting Forkhead box O1-aquaporin 5 axis mitigates neuropathic pain in a CCI rat model through inhibiting astrocytic and microglial activation.

Authors:  Yaoping Yu; Meng Wang; Xiao Yu; Yi Yan; Bo Yu; Dayin Zhang
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

2.  Effect of PKC/NF-κB on the Regulation of P2X3 Receptor in Dorsal Root Ganglion in Rats with Sciatic Nerve Injury.

Authors:  Xue Li; Jie Yuan; Xuan Yu; Qin Zhang; Bangyong Qin
Journal:  Pain Res Manag       Date:  2020-09-17       Impact factor: 3.037

Review 3.  Depression and Pain: Use of Antidepressants.

Authors:  Herlinda Bonilla-Jaime; José Armando Sánchez-Salcedo; M Maetzi Estevez-Cabrera; Tania Molina-Jiménez; José Luis Cortes-Altamirano; Alfonso Alfaro-Rodríguez
Journal:  Curr Neuropharmacol       Date:  2022       Impact factor: 7.708

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.